Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca, Pozen To Partner On Fixed-Dose Naproxen/Esomeprazole

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca will oversee global manufacturing, marketing, sales and distribution for the arthritis pain compound.
Advertisement

Related Content

Pozen to file NSAID/PPI combo
Pozen to file NSAID/PPI combo
AstraZeneca/Pozen Target 2009 For Arthritis Combination Filing
AstraZeneca/Pozen Target 2009 For Arthritis Combination Filing
AstraZeneca’s New Head Of Strategic Planning & Business Development John Goddard: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
AstraZeneca’s New Head Of Strategic Planning & Business Development John Goddard: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
GlaxoSmithKline/Pozen Anticipate Mid-2007 Launch For Trexima Migraine Combo
GlaxoSmithKline/Pozen Anticipate Mid-2007 Launch For Trexima Migraine Combo
Trexima Approvable Letter Another Headache For Pozen
Trexima Approvable Letter Another Headache For Pozen

Topics

Advertisement
UsernamePublicRestriction

Register

PS064702

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel